Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%

David R. Owens, Wolfgang Landgraf, Brian M. Frier, Mei Zhang, Philip D. Home, Luigi F Meneghini, Geremia B. Bolli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post-hoc pooled analysis of 16 randomized, treat-to-target trials involving individuals with T2DM inadequately controlled with oral anti-hyperglycaemic drugs (n = 3415) initiated on once-daily insulin glargine 100 U/mL (Gla-100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0%. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C-peptide levels. Gla-100 dose (U/kg) was highest in the poor-responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2-hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla-100 therapy, while sex and BMI were also useful indicators. However, age and C-peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Hemoglobins
Body Mass Index
Therapeutics
C-Peptide
Hypoglycemia
Glucose
Meals
Insulin
Insulin Glargine
Body Weight Changes
Glycosylated Hemoglobin A
Fasting
Logistic Models
Body Weight
Regression Analysis
Pharmaceutical Preparations

Keywords

  • basal insulin
  • glycaemic control
  • hypoglycaemia
  • meta-analysis
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes : Determinants of achievement of HbA1c goal less than 7.0%. / Owens, David R.; Landgraf, Wolfgang; Frier, Brian M.; Zhang, Mei; Home, Philip D.; Meneghini, Luigi F; Bolli, Geremia B.

In: Diabetes, Obesity and Metabolism, Vol. 21, No. 2, 01.02.2019, p. 321-329.

Research output: Contribution to journalArticle

Owens, David R. ; Landgraf, Wolfgang ; Frier, Brian M. ; Zhang, Mei ; Home, Philip D. ; Meneghini, Luigi F ; Bolli, Geremia B. / Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes : Determinants of achievement of HbA1c goal less than 7.0%. In: Diabetes, Obesity and Metabolism. 2019 ; Vol. 21, No. 2. pp. 321-329.
@article{0e2748fbb9a74c0f9f719ba4e5c579e2,
title = "Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0{\%}",
abstract = "Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post-hoc pooled analysis of 16 randomized, treat-to-target trials involving individuals with T2DM inadequately controlled with oral anti-hyperglycaemic drugs (n = 3415) initiated on once-daily insulin glargine 100 U/mL (Gla-100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0{\%} (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0{\%} (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0{\%}. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C-peptide levels. Gla-100 dose (U/kg) was highest in the poor-responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0{\%} confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2-hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0{\%} by supplementary Gla-100 therapy, while sex and BMI were also useful indicators. However, age and C-peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.",
keywords = "basal insulin, glycaemic control, hypoglycaemia, meta-analysis, type 2 diabetes",
author = "Owens, {David R.} and Wolfgang Landgraf and Frier, {Brian M.} and Mei Zhang and Home, {Philip D.} and Meneghini, {Luigi F} and Bolli, {Geremia B.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/dom.13607",
language = "English (US)",
volume = "21",
pages = "321--329",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes

T2 - Determinants of achievement of HbA1c goal less than 7.0%

AU - Owens, David R.

AU - Landgraf, Wolfgang

AU - Frier, Brian M.

AU - Zhang, Mei

AU - Home, Philip D.

AU - Meneghini, Luigi F

AU - Bolli, Geremia B.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post-hoc pooled analysis of 16 randomized, treat-to-target trials involving individuals with T2DM inadequately controlled with oral anti-hyperglycaemic drugs (n = 3415) initiated on once-daily insulin glargine 100 U/mL (Gla-100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0%. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C-peptide levels. Gla-100 dose (U/kg) was highest in the poor-responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2-hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla-100 therapy, while sex and BMI were also useful indicators. However, age and C-peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.

AB - Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c) target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes mellitus (T2DM). Materials and methods: Post-hoc pooled analysis of 16 randomized, treat-to-target trials involving individuals with T2DM inadequately controlled with oral anti-hyperglycaemic drugs (n = 3415) initiated on once-daily insulin glargine 100 U/mL (Gla-100). Clinical outcomes were assessed by HbA1c response at 24 weeks and individuals were classified as “good responders” with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/mol). Univariable and multivariable stepwise logistic regression analyses were performed to identify predictive factors for attaining HbA1c <7.0%. Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were associated with a good glycaemic response, but not age or baseline C-peptide levels. Gla-100 dose (U/kg) was highest in the poor-responder group, which had the fewest hypoglycaemia episodes. Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivariable analysis retained baseline HbA1c, body weight, BMI, sex, 2-hours PPG and diabetes duration as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and change in body weight were indicative of poor response. Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla-100 therapy, while sex and BMI were also useful indicators. However, age and C-peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin.

KW - basal insulin

KW - glycaemic control

KW - hypoglycaemia

KW - meta-analysis

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85059828890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059828890&partnerID=8YFLogxK

U2 - 10.1111/dom.13607

DO - 10.1111/dom.13607

M3 - Article

C2 - 30520217

AN - SCOPUS:85059828890

VL - 21

SP - 321

EP - 329

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -